Abhay Chinubhai Shah, part of Parmax Pharma's promoter group, acquired 249,394 shares off-market at ₹35 each, increasing their total holding to 27.20%. This filing is a regulatory step during an ongoing open offer.

Parmax Pharma Promoter Group Boosts Stake

Abhay Chinubhai Shah, acting as PAC 8, has acquired 249,394 equity shares of Parmax Pharma Ltd. The shares were purchased at ₹35.00 per share in an off-market transaction. This move raises the total shareholding of the acquirer and persons acting in concert (PACs) from 20.54% to 27.20%. The acquisition occurred on June 18, 2026, with consideration paid, though shares are pending credit to the demat account.

Reader Takeaway: Promoter group consolidation during open offer; procedural update with no immediate operational change.

What just happened

Abhay Chinubhai Shah, identified as PAC 8, bought 249,394 shares of Parmax Pharma. The purchase was done off-market at ₹35 per share from Pradeep Gosalia, Vandana Gosalia, and Nimit Gosalia.

Why this matters

This acquisition increases the promoter group's combined stake significantly. It's a required regulatory disclosure under SEBI (SAST) Regulations, 2011, related to the ongoing open offer. The enhanced holding indicates consolidation of control within the promoter-related entities.

The backstory

This transaction is part of a larger open offer process for Parmax Pharma. The filing indicates active participation and stake-building by the promoter group during this period.

What changes now

The promoter group's effective control is strengthened. Investors should view this as a step in the ongoing open offer process rather than a standalone event.

Risks to watch

No immediate risks are apparent from this filing. However, investors should monitor the progress and outcome of the open offer.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

Acquirer/PAC Holding Before: 768,320 shares (20.54%)
Acquirer/PAC Holding After: 1,017,714 shares (27.20%)
Acquisition Date: June 18, 2026
Purchase Price: ₹35.00 per share
Shares Acquired: 249,394

What to track next

Investors should closely follow further filings related to the open offer completion and any subsequent changes in the shareholding pattern of Parmax Pharma Ltd.